Drug Trial Radar · NCT00365105
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
261
Actual
Start
Jul 11, 2006
Primary completion
Jan 2012
Study completion Feb 27, 2017
Sponsor
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); NRG Oncology
- First posted
- Aug 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with or without strontium 89 or samarium 153 in treating patients with bone metastases from prostate cancer, lung cancer, or breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate, vitamin D, and calcium to see how well they work compared to zoledronate, vitamin D, calcium, and either strontium 89 or samarium 153 in preventing or delaying bone problems in patients with bone metastases from prostate cancer, lung cancer, or breast cancer.
Conditions
- Breast Cancer
- Lung Cancer
- Metastatic Cancer
- Pain
- Prostate Cancer
Interventions
CalciumDietary supplement
At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
Vitamin DDietary supplement
400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
zoledronic acidDrug
4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
Sm-153Drug
Single dose intravenously 1 mCi/kg body weight.
Sr-89Radiation
Single dose intravenously 4 mCi.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Development of a Malignant Skeletal-related Events (SRE)Time frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 80.1 months.
Locations
147 sites in 1 country. Site status is shown where the registry gives one.
Providence Cancer Center at Providence Hospital
Mobile, Alabama
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
Burbank, California
Mercy Cancer Center at Mercy San Juan Medical Center
Carmichael, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
Pomona, California
Radiation Oncology Center - Roseville
Roseville, California
Radiological Associates of Sacramento Medical Group, Incorporated
Sacramento, California
General Robert Huyser Cancer Center at David Grant Medical Center
Travis Air Force Base, California
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida
Integrated Community Oncology Network at Southside Cancer Center
Jacksonville, Florida
Baptist Medical Center South
Jacksonville, Florida
Integrated Community Oncology Network
Jacksonville Beach, Florida
Miami Cancer Center at Mercy Hospital
Miami, Florida
CCOP - Mount Sinai Medical Center
Miami Beach, Florida
Integrated Community Oncology Network - Orange Park
Orange Park, Florida
Florida Cancer Center - Palatka
Palatka, Florida
Bay Medical
Panama City, Florida
Flagler Cancer Center
Saint Augustine, Florida
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
Tampa, Florida
John B. Amos Cancer Center
Columbus, Georgia
Northeast Georgia Medical Center
Gainesville, Georgia
Northwest Community Hospital
Arlington Heights, Illinois
Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital
Downers Grove, Illinois
Ingalls Cancer Care Center at Ingalls Memorial Hospital
Harvey, Illinois
Veterans Affairs Medical Center - Hines
Hines, Illinois
Advocate Christ Medical Center
Oak Lawn, Illinois
Advocate Lutheran General Cancer Care Center
Park Ridge, Illinois
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois
Cancer Institute at St. John's Hospital
Springfield, Illinois
CCOP - Carle Cancer Center
Urbana, Illinois
Center for Cancer Care at Goshen General Hospital
Goshen, Indiana
Cancer Center at Ball Memorial Hospital
Muncie, Indiana
CCOP - Northern Indiana CR Consortium
South Bend, Indiana
McFarland Clinic, PC
Ames, Iowa
CCOP - Iowa Oncology Research Association
Des Moines, Iowa
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.